Strata Wealth Advisors LLC Reduces Stock Position in Johnson & Johnson $JNJ

Strata Wealth Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 40.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,377 shares of the company’s stock after selling 1,639 shares during the period. Strata Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $363,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. FSM Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 107.4% during the second quarter. FSM Wealth Advisors LLC now owns 8,453 shares of the company’s stock worth $1,313,000 after buying an additional 4,378 shares in the last quarter. Gill Capital Partners LLC lifted its stake in shares of Johnson & Johnson by 4.6% during the second quarter. Gill Capital Partners LLC now owns 2,365 shares of the company’s stock valued at $361,000 after buying an additional 103 shares during the period. Hoge Financial Services LLC boosted its position in Johnson & Johnson by 6.3% during the second quarter. Hoge Financial Services LLC now owns 1,381 shares of the company’s stock worth $211,000 after acquiring an additional 82 shares during the last quarter. Bleakley Financial Group LLC grew its stake in Johnson & Johnson by 1.4% in the 2nd quarter. Bleakley Financial Group LLC now owns 112,363 shares of the company’s stock worth $17,163,000 after acquiring an additional 1,543 shares during the period. Finally, Castle Wealth Management LLC raised its holdings in Johnson & Johnson by 3.4% in the 2nd quarter. Castle Wealth Management LLC now owns 4,800 shares of the company’s stock valued at $733,000 after acquiring an additional 156 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, Sanford C. Bernstein raised their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $192.31 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The firm has a market capitalization of $463.15 billion, a P/E ratio of 18.56, a P/E/G ratio of 2.27 and a beta of 0.40. The business’s 50-day simple moving average is $181.99 and its 200-day simple moving average is $165.84.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.